Home » Stocks » SGHT

Sight Sciences, Inc. (SGHT)

Stock Price: $35.44 USD -0.82 (-2.26%)
Updated Jul 27, 2021 4:00 PM EDT - Market closed
Market Cap 1.60B
Revenue (ttm) 29.78M
Net Income (ttm) -37.76M
Shares Out 45.06M
EPS (ttm) -0.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 27
Last Price $35.44
Previous Close $36.26
Change ($) -0.82
Change (%) -2.26%
Day's Open 36.20
Day's Range 34.22 - 36.71
Day's Volume 258,359
52-Week Range 27.13 - 38.25

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

New safety and efficacy data from both retrospective and prospective studies of the OMNI Surgical System and a prospective study of the TearCare System to be presented New safety and efficacy data from ...

5 days ago - GlobeNewsWire

MENLO PARK, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc., a growth-stage medical device company focused on the development and commercialization of proprietary devices that target the ...

1 week ago - GlobeNewsWire

MENLO PARK, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc., a growth-stage medical device company focused on the development and commercialization of proprietary devises that target the ...

1 week ago - GlobeNewsWire

Sight Sciences, Inc. has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC

About SGHT

Sight Sciences' mission is to transform ophthalmology and optometry through the development and commercialization of proprietary devices that target the underlying causes of the world’s most prevalent eye diseases. Sight Sciences is passionate about improving patients’ lives. Our currently marketed products, the OMNI Surgical System, or OMNI, and the TearCare System, or TearCare, target two of the world’s most prevalent and underserved eye diseases, glaucoma and dry eye disease, or DED, respectively. OMNI is a handheld, single-use, therap... [Read more...]

Industry
Medical Devices
IPO Date
Jul 15, 2021
CEO
Paul Badawi
Employees
169
Stock Exchange
NASDAQ
Ticker Symbol
SGHT
Full Company Profile

Financial Performance

In 2020, Sight Sciences's revenue was $27.64 million, an increase of 18.38% compared to the previous year's $23.35 million. Losses were -$34.69 million, 34.1% more than in 2019.

Financial Statements